Nasal Spray News and Research

RSS

HHS announcing finalized Alzheimer's plan

The plan, which includes an emphasis on research, sets 2025 as the target date for finding effective treatments for this disease.

16 May 2012

BioDiem announces new vaccine research collaboration with French-based VIVALIS

Australian vaccine development company BioDiem Ltd (ASX: BDM) today announced that it has begun a research collaboration with France-based VIVALIS (Euronext code: VLS), a biopharmaceutical company with expertise in vaccine production technologies.

9 May 2012

Oxytocin may offer hope for male sexual dysfunction

The hormone oxytocin that is also called the “love hormone” since it plays a role in the bond between a mother and baby may also improve sexual function - at least in men with Asperger’s syndrome - according to a published case report.

10 Apr 2012

MedImmune's quadrivalent flu vaccine may protect children

An intranasal vaccine that includes four weakened strains of influenza could do a better job in protecting children from the flu than current vaccines, Saint Louis University research shows.

4 Apr 2012

Nasal spray to prevent fat and plaque built up in the heart on the horizon

Researchers found a treatment that was much more effective in removing fat from arteries than established methods. The vaccine can be given as an injection or in a slightly different form as a nasal spray. A trial on 144 heart disease sufferers is under way in the US and Canada.

1 Apr 2012

FDA approves Teva's QNASL nasal aerosol corticosteroid

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.

26 Mar 2012

Meda's Astepro receives registration approval in Europe

Astepro has received registration approval in Europe via the decentralized procedure. Astepro is a new nasal spray for the treatment of allergic rhinitis.

21 Mar 2012

Meda announces positive results from three MP29-02 studies on allergic rhinitis

Meda announced today positive results of three studies of MP29-02 (tentatively called Dymista), a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate.

5 Mar 2012

Quadrivalent flu vaccine that fights against four strains of Influenza approved

The FluMist Quadrivalent vaccine from AstraZeneca's MedImmune unit protects against two strains of influenza A and two strains of influenza B, and is approved for people ages 2 to 49. Similar to the previously approved FluMist, the new vaccine is a nasal spray that delivers weakened strains of the virus. The vaccine, FluMist Quadrivalent (MedImmune), will be available for the 2013-2014 flu season.

2 Mar 2012

Nano-enabled intranasal formulation of teriparatide can treat osteoporosis

The University of Nottingham spin-out company, Critical Pharmaceuticals, has announced a -545,000 collaboration with the University to develop a nano-enabled intranasal formulation of teriparatide for the treatment of osteoporosis.

18 Feb 2012

Acorda's fourth quarter GAAP net income increases to $12.7 million

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2011.

16 Feb 2012

AstraZeneca, Impax enter license agreement to commercialize Zomig in the U.S.

Impax Pharmaceuticals, the branded products business unit of Impax Laboratories, Inc., announced today that it has licensed from AstraZeneca the exclusive United States (U.S.) commercial rights to Zomig (zolmitriptan) tablet, orally disintegrating tablet, and nasal spray formulations.

2 Feb 2012

Perrigo files ANDA and confirms Astepro Nasal Spray patent challenge

Perrigo Company announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for azelastine hydrochloride nasal spray (0.15%) and has notified Meda Pharmaceuticals, Inc., the owner of the New Drug Application (NDA) of its filing. The ANDA filing involved contributions from both Perrigo and Impax Laboratories, Inc., who will share costs and benefits of this project.

24 Jan 2012

Questions raised over nicotine replacement therapy: Study

Smokers have been advised a host of choices for nicotine replacement like gums, patches and nasal sprays to help them quit. But a new U.S. study says that these do not help people quit cigarettes over the long term any better than going it alone.

10 Jan 2012

Oxytocin can make rhesus macaques pay more attention to each other

Oxytocin, the "love hormone" that builds mother-baby bonds and may help us feel more connected toward one another, can also make surly monkeys treat each other a little more kindly.

6 Jan 2012

TheraBiogen launches Social Media campaign

TheraBiogen, Inc., a manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies, cold and flu symptoms and migraine headaches, announced today the launch of its Social Media campaign as part of its ongoing product marketing program.

26 Dec 2011

Experts warn expectant moms about dangers of common cold medicines during pregnancy

Experts in pregnancy and breastfeeding health at the California Teratogen Information Service (CTIS) Pregnancy Health Information Line warn expectant moms about the potential dangers of common cold medicines during pregnancy.

15 Dec 2011

Ampio awarded composition of matter patent for Ampion in Europe

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced receipt of notification of the granting of a European patent with broad claims directed to compositions containing DA-DKP, a cyclic dipeptide diketopiperazine which is the active ingredient of Ampion™.

7 Dec 2011

Hi-Tech Pharmacal second quarter net sales increase 27% to 56,875,000

Hi-Tech Pharmacal Co., Inc. today reported results for the Company's fiscal second quarter ended October 31, 2011.

5 Dec 2011

TU Darmstadt chemists develop new method to diagnose Alzheimer's

Chemists at the Technische Universität Darmstadt have developed a new method for diagnosing Alzheimer's disease. The method involves making protein deposits on mucous nasal membranes that are detectable years before the disease erupts visible.

16 Nov 2011